These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1880 related articles for article (PubMed ID: 26900286)

  • 1. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.
    Distrutti E; Monaldi L; Ricci P; Fiorucci S
    World J Gastroenterol; 2016 Feb; 22(7):2219-41. PubMed ID: 26900286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome.
    Harris LA; Baffy N
    Postgrad Med; 2017 Nov; 129(8):872-888. PubMed ID: 28936910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteration of the intestinal microbiota as a cause of and a potential therapeutic option in irritable bowel syndrome.
    König J; Brummer RJ
    Benef Microbes; 2014 Sep; 5(3):247-61. PubMed ID: 24583610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fecal microbiota transplantation for managing irritable bowel syndrome.
    El-Salhy M; Mazzawi T
    Expert Rev Gastroenterol Hepatol; 2018 May; 12(5):439-445. PubMed ID: 29493330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapies aimed at the gut microbiota and inflammation: antibiotics, prebiotics, probiotics, synbiotics, anti-inflammatory therapies.
    Quigley EM
    Gastroenterol Clin North Am; 2011 Mar; 40(1):207-22. PubMed ID: 21333908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Efficacy of Probiotics, Prebiotics, Synbiotics, and Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis.
    Wu Y; Li Y; Zheng Q; Li L
    Nutrients; 2024 Jul; 16(13):. PubMed ID: 38999862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiota and therapeutic approaches for dysbiosis in irritable bowel syndrome: recent developments and future perspectives.
    Dale HF; Lied GA
    Turk J Med Sci; 2020 Nov; 50(SI-2):1632-1641. PubMed ID: 32222124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is irritable bowel syndrome an infectious disease?
    Thompson JR
    World J Gastroenterol; 2016 Jan; 22(4):1331-4. PubMed ID: 26819502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microbiota in health and irritable bowel syndrome: current knowledge, perspectives and therapeutic options.
    Bonfrate L; Tack J; Grattagliano I; Cuomo R; Portincasa P
    Scand J Gastroenterol; 2013 Sep; 48(9):995-1009. PubMed ID: 23964766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probiotics, Prebiotics, and Synbiotics: Implications and Beneficial Effects against Irritable Bowel Syndrome.
    Simon E; Călinoiu LF; Mitrea L; Vodnar DC
    Nutrients; 2021 Jun; 13(6):. PubMed ID: 34203002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the gut microbiota for the treatment of irritable bowel syndrome.
    Herndon CC; Wang YP; Lu CL
    Kaohsiung J Med Sci; 2020 Mar; 36(3):160-170. PubMed ID: 31782606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A role for the gut microbiota in IBS.
    Collins SM
    Nat Rev Gastroenterol Hepatol; 2014 Aug; 11(8):497-505. PubMed ID: 24751910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy.
    Cammarota G; Ianiro G; Cianci R; Bibbò S; Gasbarrini A; Currò D
    Pharmacol Ther; 2015 May; 149():191-212. PubMed ID: 25561343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Probiotics, Prebiotics and Synbiotics in the Treatment of Irritable Bowel Syndrome: A systematic review and meta-analysis.
    Asha MZ; Khalil SFH
    Sultan Qaboos Univ Med J; 2020 Feb; 20(1):e13-e24. PubMed ID: 32190365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut microbiota as potential orchestrators of irritable bowel syndrome.
    Bennet SM; Ohman L; Simren M
    Gut Liver; 2015 May; 9(3):318-31. PubMed ID: 25918261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unraveling the ties between irritable bowel syndrome and intestinal microbiota.
    Hong SN; Rhee PL
    World J Gastroenterol; 2014 Mar; 20(10):2470-81. PubMed ID: 24627584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probiotics and irritable bowel syndrome: rationale and clinical evidence for their use.
    Barbara G; Stanghellini V; Cremon C; De Giorgio R; Gargano L; Cogliandro R; Pallotti F; Corinaldesi R
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 2():S214-7. PubMed ID: 18685517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probiotics, prebiotics, antibiotic, Chinese herbal medicine, and fecal microbiota transplantation in irritable bowel syndrome: Protocol for a systematic review and network meta-analysis.
    He Y; Xu R; Wang W; Zhang J; Hu X
    Medicine (Baltimore); 2020 Aug; 99(32):e21502. PubMed ID: 32769886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic modulation of intestinal microbiota in irritable bowel syndrome. From probiotics to fecal microbiota therapy].
    Konturek PC; Zopf Y
    MMW Fortschr Med; 2017 Dec; 159(Suppl 7):1-5. PubMed ID: 29204952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 94.